Jiangsu Sihuan Bioengineering Past Earnings Performance
Past criteria checks 0/6
Jiangsu Sihuan Bioengineering's earnings have been declining at an average annual rate of -40%, while the Biotechs industry saw earnings growing at 12% annually. Revenues have been declining at an average rate of 12.7% per year.
Key information
-40.0%
Earnings growth rate
-40.1%
EPS growth rate
Biotechs Industry Growth | 11.3% |
Revenue growth rate | -12.7% |
Return on equity | -12.3% |
Net Margin | -25.2% |
Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Jiangsu Sihuan Bioengineering makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 235 | -59 | 169 | 29 |
31 Dec 23 | 235 | -75 | 184 | 29 |
30 Sep 23 | 253 | -57 | 207 | 15 |
30 Jun 23 | 273 | -54 | 210 | 23 |
31 Mar 23 | 277 | -44 | 197 | 32 |
31 Dec 22 | 270 | -49 | 192 | 39 |
30 Sep 22 | 311 | -47 | 199 | 39 |
30 Jun 22 | 320 | -40 | 205 | 41 |
31 Mar 22 | 330 | -45 | 220 | 45 |
01 Jan 22 | 351 | -35 | 217 | 52 |
30 Sep 21 | 387 | -17 | 197 | 72 |
30 Jun 21 | 419 | -7 | 206 | 68 |
31 Mar 21 | 419 | 4 | 204 | 59 |
31 Dec 20 | 505 | 27 | 221 | 41 |
30 Sep 20 | 487 | 27 | 237 | 40 |
30 Jun 20 | 480 | 30 | 230 | 39 |
31 Mar 20 | 507 | 37 | 237 | 37 |
31 Dec 19 | 418 | 14 | 232 | 43 |
30 Sep 19 | 400 | -11 | 258 | 35 |
30 Jun 19 | 389 | -40 | 291 | 26 |
31 Mar 19 | 377 | -46 | 297 | 19 |
31 Dec 18 | 396 | -29 | 298 | 13 |
30 Sep 18 | 341 | -36 | 279 | 10 |
30 Jun 18 | 330 | -11 | 234 | 13 |
31 Mar 18 | 325 | 0 | 250 | 11 |
31 Dec 17 | 346 | 7 | 240 | 9 |
30 Sep 17 | 394 | 28 | 223 | 7 |
30 Jun 17 | 393 | 28 | 223 | 0 |
31 Mar 17 | 375 | 16 | 183 | 0 |
31 Dec 16 | 327 | 4 | 173 | 0 |
30 Sep 16 | 282 | -59 | 181 | 0 |
30 Jun 16 | 261 | -83 | 173 | 0 |
31 Mar 16 | 250 | -85 | 173 | 0 |
31 Dec 15 | 238 | -74 | 153 | 0 |
30 Sep 15 | 232 | -27 | 116 | 0 |
30 Jun 15 | 218 | -13 | 112 | 0 |
31 Mar 15 | 213 | 3 | 91 | 0 |
31 Dec 14 | 241 | 6 | 102 | 0 |
30 Sep 14 | 232 | -44 | 120 | 0 |
30 Jun 14 | 233 | -47 | 122 | 0 |
31 Mar 14 | 232 | -55 | 127 | 0 |
31 Dec 13 | 209 | -71 | 122 | 0 |
30 Sep 13 | 245 | 9 | 104 | 0 |
30 Jun 13 | 255 | 7 | 102 | 0 |
Quality Earnings: 000518 is currently unprofitable.
Growing Profit Margin: 000518 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000518 is unprofitable, and losses have increased over the past 5 years at a rate of 40% per year.
Accelerating Growth: Unable to compare 000518's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 000518 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.9%).
Return on Equity
High ROE: 000518 has a negative Return on Equity (-12.27%), as it is currently unprofitable.